Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.41 |
| ▸ | CALCR | P30988 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.39 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.39 |
| ▸ | NRP1 | O14786 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391363 | 0.93 | GRB2 (0.55) | GRB2XIAPDPP4PREPDPP7 | |
| SCHEMBL11763927 | 0.92 | GRB2 (0.51) | GRB2RAMP3CALCROPRM1OPRK1 | |
| SCHEMBL11763946 | 0.92 | GRB2 (0.51) | GRB2RAMP3CALCROPRM1OPRK1 | |
| SCHEMBL29531323 | 0.92 | GRB2 (0.48) | GRB2RAMP3CALCROPRM1OPRK1 | |
| SCHEMBL30416412 | 0.91 | GRB2 (0.47) | GRB2XIAPRAMP3CALCROPRM1 | |
| SCHEMBL29959591 | 0.91 | XIAP (0.49) | GRB2XIAPDPP4DPP7NMUR2 | |
| SCHEMBL8045396 | 0.91 | GRB2 (0.44) | GRB2XIAPRAMP3CALCROPRM1 | |
| SCHEMBL8045402 | 0.91 | GRB2 (0.44) | GRB2XIAPRAMP3CALCROPRM1 | |
| SCHEMBL194515 | 0.89 | OPRM1 (0.48) | GRB2RAMP3CALCROPRM1OPRK1 | |
| SCHEMBL1247799 | 0.89 | OPRM1 (0.48) | GRB2RAMP3CALCROPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109958-A1 | T-Cell Modulatory Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250376491-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250270284-A1 | MHC Class II Protein Constructs | CUE BIOPHARMA INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250257148-A1 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | CROSSLINK THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250243254-A1 | Interleukin-2 Polypeptides, Fusion Polypeptides, and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4587467-A2 | INTERLEUKIN-2 POLYPEPTIDES, FUSION POLYPEPTIDES, AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250197521-A1 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | CROSSLINK THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025111562-A1 | MHC CLASS II PROTEIN COMPLEXES | CUE BIOPHARMA, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250161355-A1 | PROTEINS FOR MODULATING CELL THERAPY PRODUCTS AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4547706-A1 | MHC CLASS II PROTEIN CONSTRUCTS | Cue Biopharma, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4157350-A2 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022251552-A2 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022226037-A1 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES BEARING TGF-BETA AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226058-A1 | ANTIGEN-PRESENTING POLYPEPTIDES WITH CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226024-A1 | ANTIGEN-PRESENTING POLYPEPTIDES WITH CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226054-A2 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES BEARING TGF-BETA AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022197970-A2 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197971-A1 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022099156-A2 | T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099157-A1 | ANTIGEN PRESENTING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109958-A1 | T-Cell Modulatory Polypeptides and Methods of Use Thereof | CD74, KRAS, MICA | GRB2 18/4885XIAP 924/4885RAMP3 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.